Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 15;15(6):3815-3824.
eCollection 2023.

Therapeutic effect of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy: a meta-analysis

Mingming Liu  1 , Hong Wang  2 , Ping Lv  1
Affiliations
Review

Therapeutic effect of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy: a meta-analysis

Mingming Liu et al. Am J Transl Res. .

Abstract

Objective: To comprehensively evaluate therapeutic effect of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy.

Methods: The CNKI, WanFang, VIP, Chinese Biomedical Database (CBM), PubMed, Embase and Cochrane Library databases were searched to collect the randomized controlled trials (RCTs) of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy, which were published as of March 10, 2023. Then, these articles were screened to extract and evaluate the data. Revman 5.3 was applied for data analysis.

Results: Eight RCTs involving 732 patients were included after screening. Comparing with Western medicine, YiQi HuoXue BuShen decoction combined with Western medicine enhanced the clinical effect [OR = 3.48, 95% CI: 2.12~5.73, P < 0.00001]; reduced 24-hour urine protein content [OR = -0.60, 95% CI: -0.92~-0.28, P = 0.0003], serum creatinine (Scr) [OR = -39.11, 95% CI: -44.72~-33.51, P < 0.00001], blood urea nitrogen (BUN) [OR = -2.51, 95% CI: -4.06~-0.95, P = 0.002], cystatin C (Cys-C) [OR = -0.30, 95% CI: -0.36~-0.25, P < 0.00001], Urine β2-microglobulin [OR = -0.42, 95% CI: -0.87~-0.02, P = 0.06]; and enhanced creatinine clear rate (Ccr) [OR = 3.24, 95% CI: 1.85~4.64, P < 0.00001]. In addition, the combination treatment didn't increase the incidence of adverse reaction compared with western medicine [OR = 1.55, 95% CI: 0.61~3.95, P > 0.05].

Conclusions: The combination of Yiqi Huoxue Bushen decoction and western medicine can effectively improve the clinical symptoms and renal function of patients with hypertensive nephropathy and provide more theoretical basis for clinical application.

Keywords: Western medicine; Yiqi Huoxue Bushen decoction; effect; hypertensive nephropathy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Literature screening process.
Figure 2
Figure 2
The scale for assessing the quality of clinical trials.
Figure 3
Figure 3
Summary chart of the risk bias assessment.
Figure 4
Figure 4
The comparison of total effective rate between two groups.
Figure 5
Figure 5
The comparison of 24-hour urinary protein quantification between two groups.
Figure 6
Figure 6
The comparison of serum creatinine (Scr) between two groups.
Figure 7
Figure 7
The comparison of blood urea nitrogen (BUN) between two groups.
Figure 8
Figure 8
The comparison of cystatin C (Cys-C) between two groups.
Figure 9
Figure 9
The comparison of Urine β2-microglobulin between two groups.
Figure 10
Figure 10
The comparison of creatinine clear rate (Ccr) between two groups.
Figure 11
Figure 11
The comparison of adverse reaction between two groups.
Figure 12
Figure 12
Assessment of publication bias. A. The total clinical effective rate; B. 24-hour urinary protein quantification; C. Serum creatinine (Scr); D. Blood urea nitrogen (BUN); E. Cystatin C (Cys-C); F. Urine β2-microglobulin; G. Creatinine clear rate (Ccr); H. Adverse reaction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lucero CM, Prieto-Villalobos J, Marambio-Ruiz L, Balmazabal J, Alvear TF, Vega M, Barra P, Retamal MA, Orellana JA, Gómez GI. Hypertensive nephropathy: unveiling the possible involvement of hemichannels and pannexons. Int J Mol Sci. 2022;23:15936. - PMC - PubMed
    1. Chen Z, Peng Y, Yang F, Qiang X, Chen Y, Chen Y, Cao L, Liu C, Zhang J. Traditional Chinese medicine injections combined with antihypertensive drugs for hypertensive nephropathy: a network meta-analysis. Front Pharmacol. 2021;12:740821. - PMC - PubMed
    1. Carriazo S, Vanessa Perez-Gomez M, Ortiz A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. Clin Kidney J. 2020;13:504–509. - PMC - PubMed
    1. Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28:74–79. - PubMed
    1. Jialiken D, Qian L, Ren S, Wu L, Xu J, Zou C. Combined therapy of hypertensive nephropathy with ginkgo leaf extract and dipyridamole injection and antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25852. - PMC - PubMed

LinkOut - more resources